Sakar Healthcare Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 25, 2026
- Posted by: Kunal Singla
- Category: News
The Sakar Healthcare share price target 2026 is Rs 970, implying approximately 20 percent upside from the current market price of Rs 809.1 (NSE: SAKAR). With Q4 FY26 results released in 2026 and Pharmaceutical Formulations tailwinds in focus, the Rs 970 price objective is supported by the FY27 earnings recovery thesis.
Sakar Healthcare (NSE: SAKAR) is a Pharmaceutical Formulations company trading at Rs 809.1 with a market capitalisation of Rs 1,842 crore. Analysts have set the Sakar Healthcare share price target at Rs 970 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.
Click Here – Get Free Investment Predictions
Sakar Healthcare Share Price Target 2026: Key Takeaways
- Sakar Healthcare share price target 2026: Rs 970 (20% upside from CMP Rs 809.1)
- Bull case: Rs 1,150 | Bear case: Rs 645
- Ticker: SAKAR | Sector: Pharmaceutical Formulations | MCap: Rs 1,842 crore
- 52W range: Rs 311 to Rs 889.95 | PE: 20x
- Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
- Key risk: FY27 earnings miss or FII outflows from Indian equities
Sakar Healthcare Company Overview
Sakar Healthcare (NSE: SAKAR) is an Ahmedabad-based pharmaceutical formulations company manufacturing tablets, capsules, and APIs for domestic institutional supply and regulated export markets, with FY26 revenue growing on formulation product launches. At CMP Rs 809.1 against a 52 week range of Rs 311 to Rs 889.95, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 1,842 crore with trailing PE of 20x. Compared to peers in pharma formulations sector, Sakar Healthcare is positioned as a potential re-rating candidate toward the Rs 970 price objective on FY27 earnings delivery.
| Parameter | Value |
|---|---|
| NSE Ticker | SAKAR |
| Sector | Pharmaceutical Formulations |
| CMP (2026) | Rs 809.1 |
| 52 Week High | Rs 889.95 |
| 52 Week Low | Rs 311 |
| Market Cap | Rs 1,842 crore |
| Trailing PE | 20x |
| 12-Month Analyst Target | Rs 970 |
| Bull Case Target | Rs 1,150 |
| Bear Case Target | Rs 645 |
Why Is the Sakar Healthcare Share Price Target Set at Rs 970 for 2026
FY27 Earnings Recovery and Revenue Acceleration
The Sakar Healthcare share price target of Rs 970 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 809.1.
Structural Sector Tailwinds in Pharmaceutical Formulations
The Pharmaceutical Formulations sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Sakar Healthcare’s position among peers in pharma formulations sector creates a structural growth runway, with sustained outperformance being one of the key conditions for the Rs 1,150 bull case to materialise.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Sakar Healthcare’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 970 analyst consensus.
Union Budget 2026-27 Capex Push and Policy Support
Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Sakar Healthcare’s Pharmaceutical Formulations operations, improving the probability of achieving the Rs 970 price objective through FY27 earnings delivery.
FII Flow Normalisation After the 2026 Tariff Shock
As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 20x PE, Sakar Healthcare is positioned as a beneficiary of institutional reallocation toward the Rs 1,150 bull case over the medium term.
Sakar Healthcare Share Price Targets: Short Term, 12 Month, and Long Term
Short Term Sakar Healthcare Share Price Target
Near-term support for Sakar Healthcare is anchored close to the 52 week low of Rs 311. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 809.1.
12-Month Sakar Healthcare Share Price Target 2026
The 12-month Sakar Healthcare share price target 2026 is Rs 970, implying approximately 20 percent upside from CMP Rs 809.1. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.
Long Term Sakar Healthcare Share Price Target: FY27 to FY28
The long term Sakar Healthcare share price target for FY27 to FY28 is Rs 1,150 in the bull case, requiring full earnings delivery, re-rating among peers in pharma formulations sector, and sustained institutional buying over a 2 to 3 year horizon.
Bull Case and Bear Case Scenarios for Sakar Healthcare in 2026
Bull Case Sakar Healthcare Share Price Target: Rs 1,150
The bull case Sakar Healthcare share price target of Rs 1,150 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Formulations tailwinds accelerate, and FII flows return strongly to Indian equities, representing approximately 45 percent potential upside from CMP Rs 809.1.
Bear Case Sakar Healthcare Share Price Target: Rs 645
The bear case Sakar Healthcare share price target of Rs 645 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 311.
| Scenario | Target | Key Conditions |
|---|---|---|
| Bull Case | Rs 1,150 | FY27 beat, sector re-rating, FII inflows |
| Base Case (Analyst Target) | Rs 970 | In-line FY27 delivery, partial FII recovery |
| Bear Case | Rs 645 | FY27 miss, guidance cut, FII outflows persist |
Key Risks That Could Derail the Sakar Healthcare 2026 Price Objective
Global Macro and US Tariff Headwinds
Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Sakar Healthcare share price target of Rs 970, with FII outflows being the direct transmission mechanism to Indian equity valuations.
FY27 Earnings Miss and Guidance Risk
An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 970 analyst price objective. Investors must monitor quarterly results and management commentary closely.
Competitive Intensity Among Pharmaceutical Formulations Peers
Intensifying competition from peers in pharma formulations sector could compress Sakar Healthcare’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 970 analyst target for 2026.
Liquidity Risk and FII Selling Pressure
Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.
How to Invest in Sakar Healthcare
Check the Univest Screener for live data
Before considering any investment based on the Sakar Healthcare share price target of Rs 970, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical Formulations sector demand.
Open a Demat account with a SEBI registered stockbroker to trade Sakar Healthcare (NSE: SAKAR) with full regulatory protection. Study the competitive landscape among peers in pharma formulations sector before executing any position.
Plan your entry using the 52 week low of Rs 311 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 970 price objective. Always set a stop loss below the 52 week low.
Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to track Sakar Healthcare’s live share price and receive daily stock recommendations.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.
FAQs on Sakar Healthcare Share Price Target 2026
What is the Sakar Healthcare share price target for 2026?
Ans. The Sakar Healthcare share price target 2026 is Rs 970, implying approximately 20 percent upside from CMP Rs 809.1. Bull case is Rs 1,150, bear case is Rs 645.
What was the Sakar Healthcare share price target for 2025?
Ans. The 2025 price objective for Sakar Healthcare was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 970, reflecting FY27 growth potential from CMP Rs 809.1.
Is Sakar Healthcare a good investment at Rs 809.1?
Ans. At Rs 809.1, Sakar Healthcare offers potential upside toward Rs 970 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.
What are the key risks to the Sakar Healthcare share price target 2026?
Ans. Key risks to the Sakar Healthcare share price target of Rs 970 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Formulations. Monitoring quarterly results is essential.
What is the 52 week high and low of Sakar Healthcare?
Ans. The 52 week high of Sakar Healthcare is Rs 889.95 and the 52 week low is Rs 311. At CMP Rs 809.1, the stock offers potential upside toward the Rs 970 price objective.
What are the main growth catalysts for Sakar Healthcare in 2026?
Ans. Key catalysts include FY27 PAT recovery, Pharmaceutical Formulations tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.
How does Sakar Healthcare compare to its peers?
Ans. Sakar Healthcare operates in Pharmaceutical Formulations alongside peers in pharma formulations sector. At CMP Rs 809.1 with MCap Rs 1,842 crore, it is a potential re-rating candidate toward the Sakar Healthcare share price target of Rs 970 on FY27 delivery.
What is the Sakar Healthcare share price target for 2027?
Ans. The long-term Sakar Healthcare share price target for FY27 to FY28 is Rs 1,150 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.
